Mylan announced the launch of Felbamate Tablets, the generic version of Meda‘s Felbatol

Felbamate Tablets are indicated for monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization, in adults with epilepsy. They are also indicated as adjunctive therapy in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children. 

RELATED: Seizure Drug Recalled Due To Potentially Incorrect Barcode

Felbamate, a carbamate anticonvulsant, exhibits weak inhibitory effects on GABA-receptor binding and benzodiazepine receptor binding. It is devoid of activity at the MK-801 receptor binding site of the NMDA receptor-ionophore complex. The exact mechanism by which felbamate exerts its anticonvulsant activity is unknown. 

Felbamate tablets are available in 400mg and 600mg strengths. 

For more information call (800) RX-MYLAN or visit